CSL Ltd.

EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute following expected authorization by the European Commission SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending expanding the marketing authorization for EUR neffy ® to include a 1 mg nasal adrenaline spray. EUR neffy 1 mg is for the emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products and other allergens, as well as idiopathic or exercise-induced anaphylaxis, in children who weigh ≥15 kg and <30 kg. The opinion supports an extension to EUR neffy 2 mg approval granted by the European Commission (EC) in August 2024 for the emergency treatment of anaphylaxis in adults and children who weigh ≥30 kg. Following grant of 1 mg dose, the marketing authorization will be valid in all EU member states, as well as Iceland, Liechtenstein and Norway. “The availability of a needle-free adrenaline option for younger children directly addresses one of the most significant barriers to timely treatment in this age group,” said Richard Lowenthal, Co-founder, President and CEO of ARS Pharma. “CHMP’s positive opinion marks an important milestone for families, particularly given that approximately one-quarter of epinephrine auto-injector use in Europe is for younger children weighing less than 30 kg. 1 Following the expected authorization of EUR neffy 1 mg, parents and caregivers with younger children will have a convenient, needle-free 1 mg option that they can administer quickly and confidently. As neffy (marketed as EUR neffy in the EU) continues to receive regulatory approvals and expands globally, we are focused on ensuring more families have access to a treatment option designed for practicality and ease of use when seconds matter.” neffy ’s needle-free design reduces barriers to timely treatment while fitting more naturally into everyday life. It is easy to carry, simple to use, has temperature excursions up to 50 o C (122 o F), and, if accidentally frozen, can be used once thawed without damage to the device or product within. neffy is commercially available in the U.S. for the emergency treatment of allergic reactions, including anaphylaxis, in adults and children who weigh at least 33 pounds. In 2025, ALK successfully launched EUR neffy 2 mg in selected countries throughout Europe and in the U.K. Regulatory approvals for neffy in Canada are expected in early 2026. Additionally, recent regulatory approvals for neffy occurred in Japan (with Alfresa), China (with Pediatrix Therapeutics) and in Australia (with CSL Seqirus). About neffy ® (marketed as EUR neffy in the EU) neffy is a nasal spray used for emergency treatment of allergic reactions including anaphylaxis, in adults and children aged 4 years and older who weigh 33 lbs. or greater. INDICATION AND IMPORTANT SAFETY INFORMATION FOR neffy (epinephrine nasal spray) INDICATION neffy is indicated for emergency treatment of type I allergic reactions, including anaphylaxis, in adult and pediatric patients aged 4 years and older who weigh 33 lbs. or greater. IMPORTANT SAFETY INFORMATION neffy contains epinephrine, a medicine used to treat allergic emergencies (anaphylaxis). Anaphylaxis can be life-threatening, can happen in minutes, and can be caused by stinging and biting insects, allergy injections, foods, medicines, exercise, or other unknown causes. Always carry two neffy nasal sprays with you because you may not know when anaphylaxis may happen and because you may need a second dose of neffy if symptoms continue or come back. Each neffy contains a single dose of epinephrine. neffy is for use in the nose only. Use neffy right away, as soon as you notice symptoms of an allergic reaction. If symptoms continue or get worse after the first dose of neffy , a second dose is needed. If needed, administer a second dose using a new neffy in the same nostril starting 5 minutes after the first dose. Get emergency medical help for further treatment of the allergic emergency (anaphylaxis), if needed after using neffy . Tell your healthcare provider if you have underlying structural or anatomical nasal conditions, about all the medicines you take, and about all your medical conditions, especially if you have heart problems, kidney problems, low potassium in your blood, Parkinson's disease, thyroid problems, high blood pressure, diabetes, are pregnant or plan to become pregnant, or plan to breastfeed. Tell your healthcare provider if you take or use other nasal sprays or water pills (diuretics) or if you take medicines to treat depression, abnormal heart beats, Parkinson's disease, heart disease, thyroid disease, medicines used in labor, and medicines to treat allergies. neffy and other medications may affect each other, causing side effects. neffy may affect the way other medicines work, and other medicines may affect how neffy works. neffy may cause serious side effects. If you have certain medical conditions or take certain medicines, your condition may get worse, or you may have more or longer lasting side effects when you use neffy . Common side effects of neffy include: nasal discomfort, headache, throat irritation, chest and nasal congestion, feeling overly excited, nervous or anxious, nose bleed, nose pain, sneezing, runny nose, dry nose or throat, tingling sensation, including in the nose, feeling tired, dizziness, nausea, and vomiting. Tell your healthcare provider if you have any side effects that bother you or that do not go away after using neffy . These are not all of the possible side effects of neffy . Call your healthcare provider for medical advice about side effects. To report side effects, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or the FDA at 1-800-FDA-1088 or . Please see the full Prescribing Information and Patient Information for neffy . About Type I Allergic Reactions Including Anaphylaxis Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine auto-injectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group, over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) only 3.2 million filled their active epinephrine auto-injector prescription, and of those, only half consistently carry their prescribed auto-injector. Even if patients or caregivers carry an auto-injector, more than half either delay or do not administer the device when needed in an emergency. About ARS Pharmaceuticals, Inc. ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy ® (trade name EU Rneffy ® in the EU and 优敏速® in China), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit . Forward-Looking Statements Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the patient benefits and effectiveness of neffy , including its needle-free, compact, portable and easy to use design, temperature stability, and extended shelf life; evaluations, judgments and expectations regarding regulatory processes for EUR neffy 1 mg in the EU, including the expected authorization of EUR neffy 1 mg by the European Commission, and ARS’ commercialization strategies; the anticipated timing of regulatory decisions for neffy in Canada; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “believe,” “can,” “could,” “expect,” “if,” “may,” “on track to/for,” “potential,” “plan,” “will,” “would,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharmaceuticals’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: potential safety and other complications from neffy ; the ability to obtain and maintain regulatory approval for neffy in its currently approved indications; the scope, progress and expansion of developing and commercializing neffy ; the scope, progress and expansion of developing our intranasal epinephrine technology; clinical trial results; the potential for governments and payors to delay, limit or deny coverage for neffy ; the size and growth of the market for neffy and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; ARS Pharma’s ability to protect its intellectual property position; and the impact of government laws, regulations and policies. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” in ARS Pharma’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 10, 2025. This document can also be accessed on ARS Pharma’s website at by clicking on the link “Financials & Filings” under the “Investors & Media” tab. The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharma assumes no obligation and does not intend to update these forward-looking statements, except as required by law. For more information, visit , and follow us on LinkedIn and X . ARS Investor Contact: Justin Chakma ARS Pharmaceuticals justinc@ars-pharma.com ARS Media Contact: Christy Curran Sam Brown Inc. 615.414.8668 christycurran@sambrown.com Reference: IQVIA MIDAS Database

NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche Bank provides corporates, financial institutions, hedge funds and supranational agencies around the world with trustee, agency, escrow and related services. Deutsche Bank offers a very broad range of services for diverse products, from complex securitizations and project finance to syndicated loans, debt exchanges and restructurings. * This information was provided by CSL Limited (January 2026). Depositary Receipt Information Depositary Receipt Contacts Country Australia New Business Development Nicole Pfundstein Custodian Bank BNP Paribas S.A., Level 6, 60 Castlereagh Street, Sydney NSW 2000 Tel: +61 2 8258 1019 Markets Distribution adr@db.com London Effective Date January 27, 2026 Tel: +44 (0) 20 7547 6500 gtb.db.com New York Level I ADR Tel: +1 212 250 9100 CUSIP 12637N204 ISIN US12637N2045 Symbol CSLLY Exchange OTC Current Ratio 2 ADSs: 1 ordinary share Eligibility DTC Deutsche Bank provides commercial and investment banking, retail banking, transaction banking and asset and wealth management products and services to corporations, governments, institutional investors, small and medium-sized businesses, and private individuals. Deutsche Bank is Germany’s leading bank, with a strong position in Europe and a significant presence in the Americas and Asia Pacific. The Depositary Receipts have been registered pursuant to the US Securities Act of 1933 (the "Act"). The investment or investment service which is the subject of this notice is not available to retail clients as defined by the UK Financial Conduct Authority. This notice has been approved and/or communicated by Deutsche Bank AG New York. The services described in this notice are provided by Deutsche Bank Trust Company Americas (Deutsche Bank) or by its subsidiaries and/or affiliates in accordance with appropriate local registration and regulation. Deutsche Bank is providing the attached notice strictly for information purposes and makes no claims or statement, nor does it warrant or in any way represent, as to the accuracy or completeness of the details contained herein or therein. This announcement appears as a matter of record only. Neither this announcement nor the information contained herein constitutes an offer or solicitation by Deutsche Bank or any other issuer or entity for the purchase or sale of any securities nor does it constitute a solicitation to any person in any jurisdiction where solicitation would be unlawful. No part of this notice may be copied or reproduced in any way without the prior written consent of Deutsche Bank. Past results are not an indication of future performance. Copyright© January 2026 Deutsche Bank AG. All rights reserved. Contacts For further information, please contact: Deutsche Bank AG Press & Media Relations Dylan Riddle Tel. +12122504982 Cell. +1(904)3866481 Email dylan.riddle@db.com

Concerns that Kennedy would inject vaccine skepticism into the U.S. health apparatus were rife before he was confirmed to head up the Department of Health and Human Services (HHS) early last year. While much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizer’s CEO cut to the chase this week in a blatant rebuke of HHS Secretary Robert F. Kennedy Jr., according to The Wall Street Journal.“I have very productive discussions when it comes to cancer cures, when it comes to the ‘most-favored nations’ deal, et cetera,” Pfizer’s Albert Bourla said during a WSJ event at the World Economic Forum in Davos, Switzerland. “It’s a different world when you start discussing vaccines, there’s almost like a religion there,” the CEO said, as quoted by the newspaper.On the topic of what would need to change for discussions on vaccines to advance in the U.S., Bourla responded, “[t]he Secretary of Health,” according to the Journal. The Pfizer chief also described Kennedy's vaccine position as “anti-science” during the event.Bourla's position marks a pivot from where he stood in late 2024, when he said he'd developed a “good relation with Mr. Kennedy” during a dinner at then-President-elect Donald Trump's Mar-a-Lago residence. Adding to the reasons for his confidence in the future of U.S. immunization policy, Bourla highlighted his “very long-lasting relationship” with President Trump and the COVID-19 vaccine Pfizer developed with government support through Operation Warp Speed during Trump's first term. Despite this assurance, concerns that Kennedy would inject vaccine skepticism into the U.S. health apparatus were rife before he was confirmed to head up the Department of Health and Human Services (HHS) early last year. In fact, to secure a key confirmation vote from Senator Bill Cassidy, Kennedy reportedly made a promise to “work within the current vaccine approval and safety monitoring systems,” the senator said at the time. But in the year since then, Kennedy's oversight of the U.S. vaccine infrastructure has prompted regular criticism from the senator.In June, Kennedy’s HHS ousted all 17 sitting members of the CDC’s Advisory Committee on Immunization Practices (ACIP), which helps the CDC make vaccine recommendations. He then swiftly restaffed the panel with controversial new members, some of whom are skeptical of vaccine safety and efficacy.The revamped ACIP has subsequently been mired in controversy and condemnation from major U.S. medical organizations, such as the American Academy of Pediatrics, which have accused the panel of making politicized recommendations more rooted in ideology than science. Besides the situation at ACIP, the CDC this month overhauled the United States' longstanding childhood vaccine schedule, removing prior broad vaccination recommendations for COVID, influenza, rotavirus, meningitis, hepatitis A and hepatitis B.The change followed calls from President Trump for the HHS and acting CDC director Jim O’Neill to compare the U.S.’ childhood vaccination schedule to those of peer nations. The assessment found that the U.S. is a “global outlier among developed nations” in terms of the number of diseases addressed and total doses recommended for kids, the CDC said earlier this month. Kennedy’s politicized influence at HHS and its constituent agencies has also been made clear in the high-profile departures of several federal health officials last year.Notably, Peter Marks, M.D., Ph.D.—who last year resigned abruptly from his leadership position at the FDA’s Center for Biologics Evaluation and Research (CBER), which oversees vaccines—told the Associated Press that he’d faced pressure to step aside after attempting to block Kennedy from unfettered access to the federal vaccine safety database known as VAERS.In a scathing resignation letter, Marks argued that he tried to compromise with Kennedy before realizing that “truth and transparency are not desired by the Secretary, but rather he wishes subservient confirmation of his misinformation and lies.”Bourla isn't the only CEO of a vaccine-focused drugmaker to express exasperation at Kennedy in recent weeks. During a media breakfast at the J.P. Morgan Healthcare Conference last week, Sanofi helmsman Paul Hudson noted that vaccine policy changes in the U.S. fall in line with what his company was expecting in the build-up to the 2024 election. “I've had conversations with Kennedy; we just try to stick to the facts,” Hudson explained at the event. “Not much we can do.”In 2025's third quarter, multiple large vaccine developers, including Pfizer and GSK, saw vaccine sales tick up globally while declining in the U.S., with Sanofi's CFO François Roger even remarking upon the "negative buzz" around vaccines on a conference call at the time. The vaccine sales decline was even more pronounced among companies that specialize in immunizations, such as Moderna and CSL, which backtracked plans to spin out its vaccine division last year due to the "heightened volatility in the current U.S. influenza vaccine market," according to the Australian company's chairman Brian McNamee. Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut funding to U.S. universities, framing the issue in terms of the U.S.’ health innovation race with China.“We have a meteoric rise of Chinese innovation,” the Pfizer CEO said. “They are producing serious innovation, serious science.” He also critiqued efforts by the U.S. to slow the roll of innovation coming out of China, arguing that “[y]ou can’t stop China. And you shouldn’t.” Instead, Bourla encouraged governments to adopt policies that boost their own competitiveness.“Are you going to slow [China] down in discovering new cancer medicines? Why, what is the benefit to humanity?” Bourla asked.